Register | Login
Intellectual Property Today
RFC Express - Document Management System
2015 Top Patent Firms
2014 Top Trademark Firms
Current Issue


Advertising Opportunities

Click Here

Email A Friend Back to Intellectual Property News

Perkins Coie Announces New Life Sciences Blog: 1600 PTAB

Tuesday, January 07, 2014

New Blog Focuses on Biotechnology and Organic Chemistry Decisions of the Patent Trial and Appeal Board

Perkins Coie is proud to announce the launch of 1600 PTAB, a new blog focused on patent issues affecting life sciences companies, specifically as they relate to prosecution and appeals before the Patent Trial and Appeal Board (“PTAB”). The United States Patent and Trademark Office maintains nine Patent Technology Centers - - Technology Center 1600 provides examination of biotechnology and organic chemistry applications. Perkins Coie’s 1600 PTAB blog offers legal interpretations and explanations of decisions and opinions issued by the PTAB relating to these technologies.

1600 PTAB will provide a review and analysis of interesting PTAB decisions (e.g., appeals of final rejections and adverse decisions in ex parte reexamination proceedings, as well as inter partes review and derivation opinions). 1600 PTAB seeks to provide patent practitioners with insight and strategies for handling their cases before the PTAB by highlighting arguments and strategies that are working, case law that is persuasive to the board and examiner rejections that are being overturned.

The primary authors of 1600 PTAB Blog are David Fournier and Randy Micheletti. Fournier has nearly 15 years of life sciences IP experience. He concentrates his practice on pharmaceutical, biologic, chemical, cosmetics and medical device patent matters, with particular emphasis on product exclusivity planning, development and enforcement of global patent portfolios, and client counseling under the Hatch-Waxman (pharmaceutical) and Public Health Services (biologics) Acts. Micheletti’s practice also focuses on pharmaceutical, chemical, cosmetics, medical device and biologic patent matters. He has participated in numerous post-grant proceedings, including reissues, reexaminations and foreign oppositions.

Perkins Coie’s Life Sciences attorneys represent clients across a full range of life sciences industry segments, and know the industry as well as they know the laws and regulations that apply to it. Several of the firm’s attorneys have advanced degrees in molecular biology, chemistry or biophysics, while others actively participate on the board of directors for various life sciences organizations, keeping them at the forefront of industry trends. The firm’s attorneys are skilled in both domestic and international patent preparation and prosecution before the U.S. Patent and Trademark Office with experience across a full range of life sciences areas including: biologics, biosimilars, chemistry, diagnostics, medical devices and pharmaceuticals. Additionally, Perkins Coie’s biotechnology practice is recognized nationally in tier one by U.S. News & World Report.

To read the 1600 PTAB blog report or to sign up for a customized RSS feed from the blog, please visit .

About Perkins Coie: Founded in 1912, Perkins Coie has more than 900 lawyers in 19 offices across the United States and Asia. We provide a full array of corporate, commercial litigation and intellectual property legal services to a broad range of clients, from FORTUNE 50 corporations to small, independent start-ups, as well as public and not-for-profit organizations.

Back to Intellectual Property News
Looking for...

  © Copyright 2015 Intellectual Property Today
Download Adobe Reader for free